Table 9. Evidence of risks associated with ePrescribing.
Risks | |||
Reference ID | Patient Harm | Increased Time | Increased Costs |
Ammenwerth 2008 | +/- | N/A | N/A |
Bryan 2008 | +/- | N/A | N/A |
Chatellier 1998 | +/- | N/A | N/A |
Clamp 2005 | +/- | - | +/- |
Delpierre 2004 | +/- | N/A | N/A |
Durieux 2008 | +/- | N/A | +/- |
Eslami 2007 | +/- | -/- - | - |
Eslami 2008 | +/- | -/- - | - |
Eslami 2009 | +/- | N/A | N/A |
Fitzmaurice 1998 | N/A | N/A | N/A |
Garg 2005 | +/- | N/A | N/A |
Hider 2002 | +/- | N/A | N/A |
Jamal 2009 | +/- | N/A | N/A |
Mitchell 2001 | +/- | +/- | +/- |
Mollon 2009 | +/- | N/A | +/- |
Niyazkhani 2009 | N/A | -/-- | N/A |
Poissant 2005 | N/A | -/- - | N/A |
Rothschild 2004 | N/A | +/- | +/- |
Schedlbauer 2009 | +/- | N/A | +/- |
Shamliyan 2008 | +/- | N/A | N/A |
Shekelle 2006 | +/- | N/A | +/- |
Shiffman 1999 | +/- | N/A | N/A |
Shojania 2009 | +/- | N/A | N/A |
Sintchenko 2007 | +/- | N/A | N/A |
Tan 2005 | N/A | +/- | +/- |
Van Rosse 2009 | +/- | +/- | N/A |
Wolfstadt 2008 | N/A | N/A | N/A |
Yourman 2008 | N/A | N/A | +/- |
Evidence of risks: N/A, not assessed; +/-, none; -, weak; -/- -, weak to moderate; --, moderate.